Qilu Pharmaceutical Co., Ltd., commonly known as Qilu Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Jinan, Shandong Province, China. Founded in 1992, the company has established a strong presence in various operational regions, including Asia, Europe, and North America. Specialising in the research, development, and manufacturing of innovative medicines, Qilu Pharma focuses on areas such as oncology, cardiovascular diseases, and central nervous system disorders. Its commitment to quality and innovation has led to the successful launch of several core products, including generic and proprietary drugs that stand out for their efficacy and safety. With a robust market position, Qilu Pharmaceutical has achieved notable milestones, including numerous international certifications and partnerships, solidifying its reputation as a trusted provider in the pharmaceutical landscape.
How does Qilu Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Qilu Pharmaceutical's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Qilu Pharmaceutical, headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available from the company. This lack of data suggests that Qilu Pharmaceutical may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to align with global climate goals. However, without specific emissions data or commitments from Qilu Pharmaceutical, it is challenging to assess their position in this evolving landscape. As the industry moves towards greater transparency and accountability regarding carbon emissions, it will be important for Qilu Pharmaceutical to consider developing and communicating its climate strategies to meet stakeholder expectations and contribute to global sustainability efforts.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Qilu Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.